External validation of the Endovascular aneurysm repair Risk Assessment model in predicting survival, reinterventions, and endoleaks after endovascular aneurysm repair

Objective The Endovascular aneurysm repair Risk Assessment (ERA) model predicts survival (early death, 3-year survival, and 5-year survival), reinterventions, and endoleaks after elective endovascular aneurysm repair. We externally validated the ERA model in our cohort of patients. Methods This was...

Full description

Saved in:
Bibliographic Details
Published in:Journal of vascular surgery 2014-06, Vol.59 (6), p.1555-1561.e3
Main Authors: van Beek, Sytse C., MD, Legemate, Dink A., MD, PhD, Vahl, Anco, MD, PhD, Wisselink, Willem, MD, PhD, Barnes, Mary, BappSci, Fitridge, Robert A., MS, FRACS, Balm, Ron, MD, PhD
Format: Article
Language:English
Subjects:
Aged
Aortic Aneurysm, Abdominal - surgery
Endoleak - epidemiology
Endovascular Procedures
Female
Follow-Up Studies
Humans
Incidence
Male
Netherlands - epidemiology
Reoperation - statistics & numerical data
Reproducibility of Results
Retrospective Studies
Risk Assessment - methods
ROC Curve
Surgery
Survival Rate - trends
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The Endovascular aneurysm repair Risk Assessment (ERA) model predicts survival (early death, 3-year survival, and 5-year survival), reinterventions, and endoleaks after elective endovascular aneurysm repair. We externally validated the ERA model in our cohort of patients. Methods This was a retrospective validation study of 433 consecutive patients with an asymptomatic abdominal aortic aneurysm treated with endovascular aneurysm repair in three hospitals (Amsterdam, The Netherlands) between 1997 and 2010. The area under the receiver operating characteristic curve was used as measure of accuracy (>0.70 was considered as sufficiently accurate). Results The early death rate was 1% (3 of 433; 95% confidence interval [CI], 0%-2%), the 5-year survival rate was 65% (95% CI, 61%-70%), the 5-year reintervention rate was 18% (95% CI, 14-78%), and the 5-year rate of type I, II, or III endoleak was 25% (95% CI, 20%-29%). The areas under the curve varied between 0.64 and 0.66 for predictions of survival and between 0.47 and 0.61 for reinterventions and endoleaks. Conclusions The predictions of survival, reinterventions, and endoleaks made by the ERA model were not sufficiently accurate to be used in our clinical practice.
ISSN:0741-5214
1097-6809
DOI:10.1016/j.jvs.2013.12.043